Drugs and Tuberculosis Risk in People With Type 2 Diabetes

A new study published in Nature Communications is examining whether GLP-1 receptor agonists—widely used medicines for type 2 diabetes—affect the risk of tuberculosis in people living with the disease. Researchers K.M. Liao, J.Y. Wu and C.C. Lai frame the question against two major global health challenges: metabolic disorders affecting hundreds of millions and tuberculosis, caused mainly by Mycobacterium tuberculosis. The paper explains how GLP-1 receptor agonists improve glucose control and can support weight loss, but also notes the drugs may influence immune cells and inflammatory pathways. Diabetes is already recognized as a tuberculosis risk factor through impaired immune defenses and possible effects on lung tissue.